Lymes Disease In Cats: Comprehensive Veterinary Reference Guide

Introduction

Lyme disease, or Lyme borreliosis, is a vector-borne zoonotic disease caused by the spirochete bacterium Borrelia burgdorferi sensu lato. While extensively documented in dogs and humans, the role of B. burgdorferi as a significant pathogen in domestic cats (Felis catus) has been a subject of ongoing debate and research within the veterinary community. This comprehensive reference guide provides an exhaustive, evidence-based overview of Lyme disease in cats, drawing on the latest peer-reviewed scientific publications and authoritative clinical guidelines from organizations such as the American College of Veterinary Internal Medicine (ACVIM) and the Cornell Feline Health Center.

The clinical presentation of Lyme disease in cats is often more subtle and less defined than in dogs, leading to diagnostic challenges. Many seropositive cats show no clinical signs, while others may develop fever, lethargy, lameness, or more severe systemic complications. Understanding the epidemiology, pathophysiology, diagnostic modalities, and treatment protocols is essential for veterinary practitioners and informed pet owners.

This guide is designed to serve as a definitive, publication-grade resource for veterinary professionals, researchers, and dedicated cat owners. It covers the complete spectrum of the disease, from the biology of the tick vector and the spirochete to the nuances of clinical management and prevention in both North American and European contexts.

Quick Q&A

Question: Can cats get Lyme disease from ticks? Answer: Yes, cats can become infected with Borrelia burgdorferi through the bite of an infected Ixodes tick. However, clinical disease is much less common in cats than in dogs or humans. Many infected cats remain asymptomatic, but some may develop fever, lethargy, and lameness.

Question: What are the symptoms of Lyme disease in cats? Answer: The most commonly reported symptoms include fever, lethargy, decreased appetite, and shifting-leg lameness. More rarely, cats may develop kidney inflammation (glomerulonephritis), heart rhythm abnormalities, or neurological signs. Unlike in dogs, a classic "bullseye" rash (erythema migrans) is not typically visible under fur.

Question: How is Lyme disease diagnosed in cats? Answer: Diagnosis is challenging and is based on a combination of compatible clinical signs, history of tick exposure, and positive serological tests (such as the C6 peptide antibody test). The ACVIM consensus statement recommends using the C6 assay for diagnosis, as it is specific for B. burgdorferi infection.

Question: What is the treatment for Lyme disease in cats? Answer: The recommended treatment is a course of antibiotics, typically doxycycline, administered for 30 days. Most cats show rapid clinical improvement within 24 to 48 hours. Supportive care, including fluid therapy and anti-inflammatory medications, may be necessary in severe cases.

Question: Can Lyme disease be prevented in cats? Answer: Yes, prevention focuses on rigorous tick control using veterinary-approved products (e.g., selamectin, sarolaner, fipronil) and environmental management to reduce tick exposure. A vaccine for cats is not currently available in most regions.

Question: Is Lyme disease contagious from cats to humans? Answer: No, Lyme disease is not directly contagious. Humans cannot contract the infection from an infected cat through casual contact. The disease is only transmitted through the bite of an infected tick. However, cats can bring infected ticks into the home, indirectly increasing human risk.

Etiology and Pathogenesis

The Causative Agent: Borrelia burgdorferi

Lyme disease is caused by spirochetes belonging to the Borrelia burgdorferi sensu lato (s.l.) complex. In North America, the primary pathogenic species is Borrelia burgdorferi sensu stricto (s.s.). In Europe and Asia, several genospecies are implicated, including B. afzelii, B. garinii, and B. burgdorferi s.s. [21]. These bacteria are highly motile, Gram-negative spirochetes with a unique outer membrane that lacks lipopolysaccharide but contains abundant outer surface lipoproteins (Osp), such as OspA, OspC, and OspF. These proteins play critical roles in the spirochete's life cycle within the tick vector and the mammalian host and are key targets for diagnostic testing and vaccine development.

The Tick Vector: Ixodes spp.

Transmission of B. burgdorferi occurs exclusively through the bite of infected hard ticks of the genus Ixodes. In the eastern and midwestern United States, the primary vector is the black-legged tick, Ixodes scapularis. On the Pacific coast, the western black-legged tick, Ixodes pacificus, is the principal vector. In Europe, the sheep tick Ixodes ricinus is the dominant vector, while Ixodes persulcatus is important in Asia [78].

The life cycle of Ixodes ticks typically spans two years and involves three active stages: larva, nymph, and adult. Transmission of B. burgdorferi is not immediate upon tick attachment. The spirochetes reside in the tick's midgut and must migrate to the salivary glands before they can be transmitted to the host. This process generally requires a feeding period of 24 to 48 hours, which is a critical window for prevention through early tick removal [48].

Pathogenesis in the Feline Host

The pathogenesis of Lyme disease in cats is less well understood than in dogs or humans. After inoculation via tick saliva, B. burgdorferi spirochetes disseminate locally and then systemically through the bloodstream. They have a tropism for connective tissues, joints, and the central nervous system. The spirochetes can evade the host immune response through antigenic variation, particularly of the VlsE surface protein, allowing for persistent infection.

The inflammatory response to the spirochete is driven by both bacterial components and host immune factors. Recent research has highlighted the role of B. burgdorferi peptidoglycan (PGBb) in triggering a pro-inflammatory immune response. Studies show that PGBb fragments released from live and dead spirochetes can stimulate a NOD2-dependent inflammatory pathway, which may contribute to the development of arthritis and other inflammatory lesions [30][36]. This is a key area of research, as persistent PGBb in joint tissues is hypothesized to be a driver of post-treatment Lyme arthritis in humans, and a similar mechanism may be at play in cats.

The reasons why some cats develop clinical disease while most remain asymptomatic are not fully understood. Factors likely include the host's immune status, genetic susceptibility, co-infections (such as with Feline Immunodeficiency Virus or Feline Leukemia Virus), and the specific Borrelia genospecies involved [2].

Epidemiology and Prevalence

Global and Regional Seroprevalence

The prevalence of B. burgdorferi antibodies in cats varies significantly by geographic region, reflecting the distribution of competent tick vectors.

• United States: A large-scale nationwide study of shelter cats conducted between 2007 and 2011 found a nationwide seroprevalence of 1.88% for B. burgdorferi using the IDEXX SNAP 4Dx test. The prevalence was highest in the Northeast (4.4%) and Midwest (3.4%) regions, which are highly endemic for Lyme disease. The prevalence was much lower in the South (0.2%) and West (0.0%) [7]. More recent data from 2022 to 2025 suggests a rising seroprevalence in certain regions, with a study in the eastern Tennessee valley reporting increasing rates in free-roaming felines [64][65].
• Europe: Seroprevalence in cats across Europe is highly variable. A study using a C6-peptide assay in symptomatic cats from several European countries found a seropositivity rate of 4.7% [12]. Studies in the Czech Republic have reported seroprevalences ranging from 2% to 10% depending on the region and diagnostic method used [87].
• Canada: A passive tick surveillance study in British Columbia from 2018 to 2020 detected B. burgdorferi in ticks removed from companion animals, confirming the presence of the pathogen in the region [73]. The risk is expected to increase with climate change, as modeling predicts a northward expansion of I. scapularis [17].
• Asia: Studies in mainland China have detected Lyme disease spirochetes in ticks collected from pets at a rate of 0.28%, confirming the presence of the pathogen in this region [16][61]. Seroprevalence studies in Jordan have also documented exposure in cats [86].

Risk Factors for Exposure

Several factors increase a cat's risk of exposure to B. burgdorferi:

1. Outdoor Access: Cats that spend time outdoors, especially in wooded, grassy, or brushy areas, have a significantly higher risk of tick exposure. Free-roaming cats are at the greatest risk.
2. Geographic Location: Living in or traveling to regions known to be endemic for Lyme disease is the primary risk factor.
3. Lack of Tick Prevention: Cats not receiving regular veterinary-approved tick preventatives are at higher risk.
4. Co-infections: Cats infected with FIV or FeLV may have a weakened immune system, potentially making them more susceptible to clinical disease following B. burgdorferi infection [2].
5. Seasonality: The risk of tick bites is highest during the spring, summer, and fall months when Ixodes nymphs and adults are most active.

Clinical Signs in Cats

The clinical presentation of Lyme disease in cats is notoriously variable and often non-specific. The ACVIM consensus update on Lyme borreliosis in dogs and cats notes that while experimental infection can induce clinical signs, naturally occurring clinical disease in cats appears to be rare [48][96]. It is crucial for veterinarians to maintain a high index of suspicion in endemic areas.

Common Clinical Signs

When clinical signs do occur, they typically manifest weeks to months after the tick bite. The most frequently reported signs include:

• Fever: An acute, often transient fever is a common finding.
• Lethargy and Depression: Affected cats may become listless, less interactive, and sleep more than usual.
• Anorexia: A decreased appetite or complete refusal to eat is frequently observed.
• Lameness: A shifting-leg lameness, similar to that seen in dogs, has been reported. This is due to acute arthritis or polyarthritis. The lameness may be mild and intermittent.
• Joint Swelling and Pain: Physical examination may reveal swollen, warm, and painful joints.

Less Common and Severe Manifestations

More severe manifestations are rare but have been documented in the veterinary literature:

• Lyme Nephritis (Glomerulonephritis): This is a severe and potentially fatal complication, though it is much less common in cats than in dogs. It results from the deposition of immune complexes in the renal glomeruli, leading to proteinuria and progressive kidney disease. The ACVIM consensus statement highlights that while B. burgdorferi infection is a recognized cause of glomerulonephritis in dogs, its role in feline kidney disease is less clear [48].
• Cardiac Disease: Lyme carditis, causing bradyarrhythmias (slow heart rate) and heart block, has been documented in cats. A 2020 case report described two cats with Lyme borreliosis presenting with cardiac bradydysrhythmia, which resolved with antibiotic therapy [92].
• Neurological Signs: Neurological involvement (neuroborreliosis) is rare but can occur. Signs may include facial nerve paralysis, behavioral changes, or seizures.
• Ocular Signs: Uveitis (inflammation of the uveal tract of the eye) has been anecdotally associated with Lyme disease in cats.

The Asymptomatic Carrier State

A significant proportion of cats that are seropositive for B. burgdorferi show no clinical signs whatsoever [7]. These cats are considered to be in a carrier state. The significance of this carrier state is a major area of debate. It is unclear whether these cats will eventually develop clinical disease or if the infection is effectively controlled by their immune system. Current consensus suggests that treatment of asymptomatic seropositive cats is not routinely recommended in the absence of clinical signs or significant proteinuria [48].

Diagnosis

Diagnosing Lyme disease in cats is challenging and requires a systematic approach. The ACVIM consensus statement provides clear guidance on the diagnostic workup [48][96].

Clinical History and Physical Examination

The diagnostic process begins with a thorough history, including:

• Tick Exposure: A known or possible history of tick exposure (outdoor access, living in endemic area).
• Clinical Signs: Documentation of compatible signs such as fever, lethargy, and shifting leg lameness.
• Response to Therapy: A history of clinical improvement following antibiotic administration can be a strong diagnostic clue.

A complete physical examination should assess for pyrexia, joint pain or effusion, lymphadenomegaly, and cardiac or neurological abnormalities.

Laboratory Testing

1. In-House Serological Screening (SNAP 4Dx Plus Test)

The IDEXX SNAP 4Dx Plus Test is a widely used point-of-care ELISA that detects antibodies to B. burgdorferi (specifically the C6 peptide), Anaplasma spp., Ehrlichia spp., and antigen of Dirofilaria immitis (heartworm). This test is validated for use in cats [7][65]. A positive result for B. burgdorferi indicates exposure to the spirochete but does not confirm active clinical disease.

2. Confirmatory C6 Peptide Antibody Test

The ACVIM consensus statement recommends the C6 peptide antibody test as the preferred serological test for diagnosing B. burgdorferi infection in cats. The C6 peptide is based on the VlsE surface protein of B. burgdorferi and is highly specific, meaning it does not cross-react with antibodies from other Borrelia species or other bacteria. A quantitative C6 antibody test is available (the Quant C6 test), which can measure antibody levels. While a high C6 antibody level has been correlated with clinical disease in dogs, this correlation is not as well established in cats [48].

3. Immunoblotting (Western Blot)

Immunoblotting can be used to confirm positive ELISA results by identifying antibodies to specific Borrelia proteins. While less commonly used as a first-line test in cats, it can be helpful in complex cases. Newer single-step immunoblot tests using recombinant protein antigens are being developed and may offer improved sensitivity for detecting early-stage disease [60].

4. Complete Blood Count (CBC) and Serum Biochemistry

These tests are non-specific but are essential for assessing the overall health of the cat and ruling out other diseases. Findings in cats with Lyme disease may include:

• CBC: Mild anemia or neutrophilia.
• Biochemistry: Elevated globulins, mild increases in liver enzymes.
• Urinalysis: Proteinuria is a critical finding, as it may indicate Lyme nephritis.

5. Polymerase Chain Reaction (PCR)

PCR testing on blood, synovial fluid, or tissue biopsies can detect the DNA of B. burgdorferi. While highly specific, PCR is often insensitive in cats because the spirochetes are present in low numbers in the blood and tissues during clinical illness. A negative PCR does not rule out Lyme disease. PCR is more useful for research purposes or in cases where other diagnostics are inconclusive [12][16].

Differential Diagnoses

The clinical signs of Lyme disease are non-specific, and a wide range of other conditions must be considered, especially in a cat presenting with fever and lameness. Key differentials include:

• Other Tick-Borne Diseases: Anaplasmosis, ehrlichiosis, and babesiosis can cause similar clinical signs [2][16].
• Feline Infectious Peritonitis (FIP): Can cause fever, lethargy, and systemic inflammation.
• Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV): These retroviruses can cause chronic illness and immunosuppression [2].
• Bacterial Arthritis: Caused by other bacteria (e.g., Mycoplasma spp., Staphylococcus spp.).
• Immune-Mediated Polyarthritis: A non-infectious inflammatory joint disease.
• Pancreatitis: Can present with fever, lethargy, and anorexia.
• Trauma: A common cause of acute lameness in cats.

Diagnostic Algorithm

A practical diagnostic approach for a cat with suspected Lyme disease is as follows:

1. Step 1: Perform a thorough history and physical exam. Assess for tick exposure and compatible clinical signs.
2. Step 2: Run a CBC, serum biochemistry, and urinalysis (with UPC ratio) to assess for systemic disease and proteinuria.
3. Step 3: Perform an in-house SNAP 4Dx Plus Test.
4. Step 4: If the SNAP test is positive for B. burgdorferi and clinical signs are compatible, a diagnosis of suspected Lyme disease is made.
5. Step 5: Consider sending a confirmatory quantitative C6 antibody test to the laboratory.
6. Step 6: Rule out other differential diagnoses, especially other tick-borne diseases and FIV/FeLV.
7. Step 7: If clinical signs resolve with antibiotic therapy, this further supports the diagnosis.

Treatment and Management

Antibiotic Therapy

The cornerstone of treatment for confirmed or suspected clinical Lyme disease in cats is antibiotic therapy. The drug of choice is doxycycline.

• Drug: Doxycycline hyclate or monohydrate.
• Dose: 10 mg/kg orally every 24 hours, or 5 mg/kg every 12 hours.
• Duration: The recommended duration of therapy is 30 days. Shorter courses may be ineffective at clearing the infection.
• Administration: Doxycycline tablets or capsules should be administered with food or water to reduce the risk of esophagitis (esophageal stricture), a known adverse effect in cats. The tablet should be followed by a small amount of water or food to ensure it passes into the stomach.
• Alternatives: If doxycycline is not tolerated, amoxicillin (22 mg/kg orally every 8 to 12 hours for 30 days) is a potential second-line option, though it is generally considered less effective.

Supportive Care

In addition to antibiotics, supportive care is crucial for managing clinical signs:

• Fluid Therapy: Intravenous or subcutaneous fluids may be necessary for dehydrated or anorexic cats.
• Anti-Inflammatories: Non-steroidal anti-inflammatory drugs (NSAIDs) can be used to manage fever and joint pain, but they must be used with caution in cats and only after ensuring adequate hydration and renal function. Meloxicam is a commonly used NSAID in cats, but its use should be carefully monitored.
• Appetite Stimulants: If anorexia persists, appetite stimulants such as mirtazapine may be used.

Management of Complications

• Lyme Nephritis: If significant proteinuria is detected (UPC > 0.4), this is a serious complication. Treatment involves aggressive antibiotic therapy, a renal-protective diet, and medications to reduce proteinuria. The ACVIM consensus statement for dogs suggests using an angiotensin receptor blocker (ARB) like telmisartan to manage proteinuria, and this is a reasonable approach in cats as well [1][49]. The prognosis for cats with Lyme nephritis is guarded.
• Lyme Carditis: Cats with cardiac arrhythmias should be hospitalized for cardiac monitoring. The arrhythmia typically resolves with antibiotic therapy, but temporary supportive care may be needed [92].

Treatment of Asymptomatic Seropositive Cats

The current consensus, as outlined by the ACVIM, is that treatment of asymptomatic seropositive cats is not routinely recommended. The rationale is that most cats will clear the infection on their own or remain healthy carriers without adverse effects. However, treatment should be considered if:

• The cat has significant proteinuria (UPC > 0.4).
• The cat is being treated for another concurrent illness.
• The owner is highly concerned and requests treatment after a full discussion of the risks and benefits.

Prognosis

The prognosis for cats with uncomplicated Lyme disease is generally excellent. Most cats show a rapid improvement in clinical signs within 24 to 48 hours of starting antibiotic therapy. The prognosis is guarded for cats that develop severe complications such as Lyme nephritis or neuroborreliosis.

Prevention

Prevention is the most effective strategy for managing Lyme disease in cats. It relies on a multi-modal approach.

Tick Control Products

The use of veterinary-approved, broad-spectrum tick preventatives is the single most important preventive measure. Products should be used year-round in endemic areas.

• Topical Spot-Ons: Products containing fipronil, selamectin, or fluralaner are effective against Ixodes ticks.
• Oral Chewables: Fluralaner and sarolaner are available as oral chews for cats and provide effective tick control.
• Collars: Flumethrin/imidacloprid collars (e.g., Seresto) provide long-lasting tick protection.

A recent study demonstrated the efficacy of a combination product containing selamectin and sarolaner (Revolution Plus) in preventing the transmission of B. burgdorferi from infected I. scapularis to cats [62]. This confirms that modern tick preventatives can effectively block disease transmission.

Environmental Management

• Habitat Modification: Keep cats away from tick habitats such as wooded areas, tall grass, and leaf litter. Creating a tick-safe zone in the yard by keeping grass short and removing brush can help.
• Tick Checks: Perform daily tick checks on cats that go outdoors. Pay close attention to the head, neck, ears, and between the toes. Prompt removal of attached ticks (within 24 hours) can prevent transmission.

Vaccination

Currently, there is no commercially available Lyme disease vaccine for cats in the United States, Canada, or Europe. Vaccines are available for dogs, but they are not licensed for use in cats. Research into a feline vaccine is ongoing, but none is expected in the near future.

The One Health Perspective

Lyme disease is a classic example of a One Health issue, where the health of humans, animals, and the environment is interconnected. Cats can serve as sentinels for Lyme disease risk in a given area. Studies have shown a correlation between the number of I. scapularis ticks collected from pets and the incidence of human Lyme disease in the same region [37][98]. Furthermore, pet ownership has been identified as a risk factor for human tick encounters, as pets can bring ticks into the home environment [99]. Therefore, protecting cats from ticks not only benefits the cat but also helps protect the human family.

Special Considerations

Lyme Disease in Cats vs. Dogs

It is important to distinguish between Lyme disease in cats and dogs, as the disease manifests differently.

| Feature | Dogs | Cats | | :-, | :-, | :-, | | Clinical Signs | Fever, lethargy, shifting-leg lameness, acute arthritis. | Fever, lethargy, anorexia, shifting-leg lameness. Often more subtle. | | Lyme Nephritis | A well-recognized, severe complication. | Rare, but can occur. Less well-characterized. | | Asymptomatic Rate | High (up to 90% in endemic areas). | Very high. Most seropositive cats are asymptomatic. | | Vaccination | Widely available and recommended. | Not available. | | Diagnostic Testing | SNAP 4Dx Plus and C6 test are standard. | SNAP 4Dx Plus and C6 test are validated and recommended. | | Treatment | Doxycycline for 30 days. | Doxycycline for 30 days. |

Lyme Disease in Cats vs. Humans

• Rash: The classic erythema migrans ("bullseye") rash is a hallmark of early Lyme disease in humans but is not visible in cats due to their fur coat.
• Neurological Signs: Neuroborreliosis is more common in humans (e.g., facial palsy, meningitis) than in cats.
• Chronic Lyme: The concept of "chronic Lyme disease" is controversial in human medicine and is not recognized as a distinct clinical entity in cats.

Pediatric and Geriatric Considerations

• Kittens: Kittens are at risk of tick exposure if they go outdoors. The safety and efficacy of many tick preventatives are established for kittens over 8 weeks of age. Treatment with doxycycline is generally safe, but the risk of esophageal stricture is a concern, and the medication must be administered carefully.
• Senior Cats: Older cats are more likely to have concurrent diseases (e.g., chronic kidney disease, hyperthyroidism) that can complicate the diagnosis and treatment of Lyme disease. A thorough pre-treatment evaluation, including renal function testing, is essential.

Future Directions and Research

The understanding of Lyme disease in cats continues to evolve. Key areas of future research include:

• Improved Diagnostics: The development of more sensitive and specific tests for early and active infection is a high priority. Novel diagnostics that do not rely solely on serology are urgently needed [55].
• Pathogenesis: Further research is needed to understand the mechanisms that cause some cats to develop clinical disease while others remain asymptomatic. The role of the feline immune system and co-infections is a critical area of study [2].
• Treatment: Studies are needed to evaluate the optimal duration of antibiotic therapy and to explore alternative treatments for persistent infections. The development of new antibiotics, such as the peptide deformylase inhibitor forazemin, shows promise for treating Lyme disease in humans and may eventually have applications in veterinary medicine [59].
• Vaccine Development: The development of a safe and effective vaccine for cats would be a game-changer for prevention.
• Climate Change Impact: As climate change expands the geographic range of Ixodes ticks, the risk of Lyme disease in cats is expected to increase in many regions, including Canada and northern Europe [17].

Conclusion

Lyme disease in cats is a complex and often under-recognized condition. While clinical disease is rare compared to dogs, it is a legitimate differential diagnosis for any cat in an endemic area presenting with fever, lethargy, and lameness. The diagnosis requires a high index of suspicion and is supported by serological testing, particularly the C6 peptide antibody test. Treatment with doxycycline is highly effective, and the prognosis for uncomplicated cases is excellent.

Prevention through rigorous tick control is paramount, as no vaccine is currently available. By understanding the nuances of this disease, veterinarians and pet owners can work together to protect feline health and, through a One Health approach, contribute to the broader effort to control Lyme disease.

References

[1] Han, D., Lee, D. G., & Jung, D. (2018). Evaluation of effect over time after oral administration of telmisartan for chronic kidney disease in cats. Journal of Biomedicine and Translational Research. [2] So-In, C., Watayotha, L., Sonsupee, T., et al. (2025). Molecular Detection of Vector-Borne Pathogens and Their Association with Feline Immunodeficiency Virus and Feline Leukemia Virus in Cats from Northeastern Thailand. Animals. [7] Smith, R. C., Starkey, L., Bowles, J., et al. (2024). Nationwide Seroprevalence of Dirofilaria immitis Antigen and Antibodies to Borrelia burgdorferi, Anaplasma spp., and Ehrlichia spp. in Shelter Cats in the United States, 2007-2011. Parasitologia. [12] Pantchev, N., Vrhovec, M. G., Pluta, S., et al. (2016). Seropositivity of Borrelia burgdorferi in a cohort of symptomatic cats from Europe based on a C6-peptide assay with discussion of implications in disease aetiology. Berliner und Munchener tierarztliche Wochenschrift. [16] Ye, Q., Zhang, G. X., Wang, R., et al. (2026). Survey of tick species and tick-borne pathogens in pet dogs and cats in mainland China. Veterinary Parasitology. [17] Ripoche, M., Irace-Cima, A., Adam-Poupart, A., et al. (2023). Current and future burden from Lyme disease in Quebec as a result of climate change. Canada Communicable Disease Report. [21] Higgs, S., & Brissette, C. (2023). An Overview of Lyme Disease in Europe. Vector Borne and Zoonotic Diseases. [30] McCausland, J. W., Kloos, Z., Irnov, I., et al. (2025). Bacterial and host enzymes modulate the pro-inflammatory response elicited by the peptidoglycan of Lyme disease agent Borrelia burgdorferi. PLoS Pathogens. [36] McCausland, J. W., Kloos, Z., Irnov, I., et al. (2025). Bacterial and host enzymes modulate the inflammatory response produced by the peptidoglycan of the Lyme disease agent. bioRxiv. [37] Hendricks, B. M., Mark-Carew, M., & Conley, J. (2017). Evaluating the utility of companion animal tick surveillance practices for monitoring spread and occurrence of human Lyme disease in West Virginia, 2014-2016. Geospatial Health. [48] Littman, M. P., Gerber, B., Goldstein, R. E., et al. (2018). ACVIM consensus update on Lyme borreliosis in dogs and cats. Journal of Veterinary Internal Medicine. [49] Han, D., & Jung, D. (2019). Long term effects after telmisartan administration for cardiovascular-renal axis disorder in cats. Journal. [55] Horn, E. J., Menefee, B., Schotthoefer, A. M., et al. (2026). Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples. Journal of Clinical Microbiology. [59] Lewis, K., Patil, P., Liang, H. W., et al. (2026). A deformylase inhibitor expands therapeutic options for Lyme disease. Research Square. [60] Shah, J., Liu, S., Calalo-Ramos, C., et al. (2026). Single-step immunoblot tests with recombinant protein antigens for detecting IgG and IgM antibodies in Lyme disease. Microbiology Spectrum. [61] Ye, Q., Zhang, G., Wang, R., et al. (2026). Survey of tick species and tick-borne pathogens in pet dogs and cats in mainland China. Veterinary Parasitology. [62] Isdale, R., Myers, J. A. E., Holzmer, S., et al. (2026). Efficacy of Revolution(®) Plus (selamectin plus sarolaner) for the prevention of transmission of Borrelia burgdorferi from infected Ixodes scapularis to cats. Parasites & Vectors. [64] Black, C., Pruitt, S., & Weisent, J. (2026). Rising seroprevalence of Borrelia spp. in free roaming felines in the eastern Tennessee valley. Veterinary Parasitology. [65] Smith, R. C., Barrantes Murillo, D. F., Mitchell, J., et al. (2025). Seroprevalence of selected vector-borne agents in pet cats using the SNAP® 4Dx® PLUS, United States, 2022-2025. Veterinary Parasitology: Regional Studies and Reports. [73] Fraser, E., Iwasawa, S., Chahil, N., et al. (2024). Passive tick surveillance and detection of Borrelia burgdorferi in ticks from companion animals in British Columbia: 2018 to 2020. Canadian Veterinary Journal. [78] Gandy, S. L., Hansford, K. M., & Medlock, J. M. (2023). Possible expansion of Ixodes ricinus in the United Kingdom identified through the Tick Surveillance Scheme between 2013 and 2020. Medical and Veterinary Entomology. [87] Zakovská, A., Schánilec, P., Treml, F., et al. (2020). Seroprevalence of Antibodies against Borrelia burgdorferi s. l. and Leptospira interrogans s. l. in Cats in district of Brno and its environs, the Czech Republic. Annals of Agricultural and Environmental Medicine. [92] Törnqvist-Johnsen, C., Dickson, S. A., Rolph, K., et al. (2020). First report of Lyme borreliosis leading to cardiac bradydysrhythmia in two cats. JFMS Open Reports. [96] Littman, M. P., Gerber, B., Goldstein, R. E., et al